Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity

Neuropathology and Applied Neurobiology

Volumn 40, Issue 2, 2014, Pages 205-216

  Baumgarten, P ^a   Harter, P N ^a   Tonjes M ^b   Capper, D ^b,c   Blank, A E ^a   Sahm, F ^b,c   von Deimling, A ^b,c   Kolluru, V ^d   Schwamb, B ^d   Rabenhorst, U ^d,g   Starzetz, T ^a   Kogel D ^e   Rieker, R J ^f   Plate, K H ^a   Ohgaki, H ^h   Radlwimmer, B ^b   Zornig M ^d   Mittelbronn, M ^a  

^a GOETHE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^g KAROLINSKA INSTITUTE   (Sweden)

^h INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Astrocytoma; FUBP1; IDH1; Ki 67; Oligodendroglioma

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; PROTEIN; PROTEIN FUBP1; UNCLASSIFIED DRUG;

ARTICLE; CANCER GENETICS; CARCINOGENESIS; CHROMOSOME 19Q; CHROMOSOME 1P; FUBP1 GENE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GLIOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IDH1 GENE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; NERVE CELL DIFFERENTIATION; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ASTROCYTOMA; FUBP1; IDH1; KI-67; OLIGODENDROGLIOMA;

CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; CODON, NONSENSE; DNA HELICASES; DNA-BINDING PROTEINS; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; LOSS OF HETEROZYGOSITY; NEURONS; OLIGODENDROGLIOMA;

EID: 84892662162     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/nan.12088     Document Type: Article

References (18)

1. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, Rodriguez FJ, Cahill DP, McLendon R, Riggins G, Velculescu VE, Oba-Shinjo SM, Marie SK, Vogelstein B, Bigner D, Yan H, Papadopoulos N, Kinzler KW. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011; 333: 1453-1455
2. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol (Berl) 2009; 118: 469-474
3. Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y, Tanaka Y, Vital A, Mariani L, Stawski R, Watanabe T, De Girolami U, Kleihues P, Ohgaki H. Molecular classification of low-grade diffuse gliomas. Am J Pathol 2010; 177: 2708-2714
4. Sahm F, Koelsche C, Meyer J, Pusch S, Lindenberg K, Mueller W, Herold-Mende C, von Deimling A, Hartmann C. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol (Berl) 2012; 123: 853-860
5. Duncan R, Bazar L, Michelotti G, Tomonaga T, Krutzsch H, Avigan M, Levens D. A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes Dev 1994; 8: 465-480
6. Rabenhorst U, Beinoraviciute-Kellner R, Brezniceanu ML, Joos S, Devens F, Lichter P, Rieker RJ, Trojan J, Chung HJ, Levens DL. Zörnig M. Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth. Hepatology 2009; 50: 1121-1129
7. Liu J, Chung HJ, Vogt M, Jin Y, Malide D, He L, Dundr M, Levens D. JTV1 co-activates FBP to induce USP29 transcription and stabilize p53 in response to oxidative stress. EMBO J 2011; 30: 846-858
8. Barthéléry M, Jaishankar A, Salli U, Freeman WM, Vrana KE. 2-D DIGE identification of differentially expressed heterogeneous nuclear ribonucleoproteins and transcription factors during neural differentiation of human embryonic stem cells. Proteomics Clin Appl 2009; 3: 505-514
9. Ko HS, Lee Y, Shin JH, Karuppagounder SS, Gadad BS, Koleske AJ, Pletnikova O, Troncoso JC, Dawson VL, Dawson TM. Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proc Natl Acad Sci U S A 2010; 107: 16691-16696
10. Williams BY, Hamilton SL, Sarkar HK. The survival motor neuron protein interacts with the transactivator FUSE binding protein from human fetal brain. FEBS Lett 2000; 470: 207-210
11. Malz M, Weber A, Singer S, Riehmer V, Bissinger M, Riener MO, Longerich T, Soll C, Vogel A, Angel P, Schirmacher P, Breuhahn K. Overexpression of far upstream element binding proteins: a mechanism regulating proliferation and migration in liver cancer cells. Hepatology 2009; 50: 1130-1139
12. Singer S, Malz M, Herpel E, Warth A, Bissinger M, Keith M, Muley T, Meister M, Hoffmann H, Penzel R, Gdynia G, Ehemann V, Schnabel PA, Kuner R, Huber P, Schirmacher P, Breuhahn K. Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. Cancer Res 2009; 69: 2234-2243
13. Weber A, Kristiansen I, Johannsen M, Oelrich B, Scholmann K, Gunia S, May M, Meyer HA, Behnke S, Moch H, Kristiansen G. The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer. BMC Cancer 2008; 8: 369
14. Atanassov BS, Dent SY. USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1. EMBO Rep 2011; 12: 924-930
15. Ko HS, Kim SW, Sriram SR, Dawson VL, Dawson TM. Identification of far upstream element-binding protein-1 as an authentic Parkin substrate. J Biol Chem 2006; 281: 16193-16196
16. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumors of the Central Nervous System, Lyon: IARC, 2007
17. Griffin CA, Burger P, Morsberger L, Yonescu R, Swierczynski S, Weingart JD, Murphy KM. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006; 65: 988-994
18. Watanabe T, Nakamura M, Kros JM, Burkhard C, Yonekawa Y, Kleihues P, Ohgaki H. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol (Berl) 2002; 103: 267-275